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Abstract
Background: Mobility problems are present in 70–80% of stroke survivors and can result in impaired gait and
reduced physical activity limiting independent living. Auditory rhythmic cueing (ARC) has been used to provide
auditory feedback and shows promise in improving a variety of walking parameters following stroke. The aim of
this pilot study is to assess the feasibility of conducting a multi-centre, observer blind, randomised controlled trial of
auditory rhythmical cueing (ARC) intervention in home and community settings in North East England.
Methods: This pilot observer blind randomised controlled feasibility trial aims to recruit 60 participants over 15
months from community stroke services in the North East of England. Participants will be within 24 months of
stroke onset causing new problems with mobility. Each participant will be randomised to the study intervention or
control group. Intervention treatment participants will undertake 18 auditory rhythmical cueing (ARC) treatment
sessions over 6 weeks (3 × 30 min per week, 6 supervised (physiotherapist/research associate)/12 self-managed) in a
home/community setting. A metronome will be used to provide ARC during a series of balance and gait exercises,
which will be gradually progressed. The control treatment participants will undertake the same duration balance
and gait exercise training programme as the intervention group but without the ARC. Feasibility will be determined
in terms of recruitment, retention, adverse events, adherence, collection of descriptive clinical and accelerometer
motor performance data at baseline, 6 weeks and 10 weeks and description of participant, provider and clinical
therapists’ experiences. As well as using questionnaires to collate participant views, qualitative interviews will be
undertaken to further understand how the intervention is delivered in practice in a community setting and to
identify aspects perceived important by participants.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: s.a.moore@newcastle.ac.uk
1Stroke Research Group, Institute of Neuroscience Newcastle University, 3-4
Claremont Terrace, Newcastle upon Tyne, UK
4Stroke Northumbria, Northumbria Healthcare NHS Foundation Trust, Rake
Lane, North Shields, Tyne and Wear NE29 8NH, UK
Full list of author information is available at the end of the article
McCue et al. Pilot and Feasibility Studies            (2020) 6:68 
https://doi.org/10.1186/s40814-020-00605-1
(Continued from previous page)
Discussion: The ACTIVATE study will address an important gap in the evidence base by reporting whether it is
feasible to deliver auditory rhythmical cueing in the home and community to improve gait and balance parameters
following stroke. The feasibility of the study protocol will be established and results will inform the design of a
future multi-centre randomised controlled trial.
Trial registration: Trial register: ISRCTN, Trial identifier: ISRCTN10874601: Date of registration: 12/03/2018.
Keywords: Stroke, Gait and exercise, Auditory rhythmical cueing, Feasibility, Randomised controlled trial
Background
Mobility problems are present in 70–80% of stroke sur-
vivors [1], often resulting in impaired gait, which persists
despite rehabilitation [2], and reduced physical activity
[3]. There are 1.2 million stroke survivors in the UK
alone [4], equating to around 840,000 to 960,000 people
currently struggling with mobility problems. Gait im-
pairments commonly observed include reduced walking
speed, decreased stride length/cadence [5, 6] and in-
creased temporal asymmetry [7], which limits home and
community ambulation and is associated with increased
dependency and reduced quality of life [8]. Discovering
treatments that target gait impairment, balance and mo-
bility are viewed as one of the top priorities in life after
stroke [9].
A recent systematic review [10] examined the use of
auditory rhythmical cueing (ARC) in motor rehabilita-
tion. ARC provides auditory feedback usually delivered
via music or metronome [11, 12] to improve gait and
physical activity post-stroke. This review found that
stroke patients showed significantly greater walking vel-
ocity and improvements in cadence and stride length
after intervention with ARC compared to control groups
receiving traditional rehabilitative or other types of inter-
vention. Several other systematic reviews on the use of
ARC in motor recovery after stroke reported promising
results finding improvements in selected gait parameters
[2, 11, 13]. The benefit of ARC-based gait interventions
include implementation during functional tasks in home
and community settings, sustained walking practice in
urban and rural environments and overall increased task
practice (a recognised key component in recovery post-
stroke) [12, 14].
Much of the work to date on ARC has been ward or
laboratory based, with many studies using treadmill
walking [2, 15], limiting application of findings to ‘real
world’ ambulation. One recent study however has ad-
dressed the feasibility and potential efficacy of a home-
based ARC training programme for stroke survivors and
reported that this was feasible and well tolerated [16].
However, whilst finding improvements in walking and
functional mobility, the training involved stepping in
place/marching on the spot and these activities may not
translate to community mobility. Although targeting gait
in the home is important, walking in the community is a
key activity for stroke survivors which, for many, is still
unachievable and as a result they are confined to home
[17, 18]. Developing an ARC programme that is deliver-
able in the home and community may assist more indi-
viduals with stroke to mobilise safely beyond their front
door.
Resources for therapy-led rehabilitation are often time
limited and vary across the UK [19]. Alternative ap-
proaches need to be sought for long-term therapy man-
agement post-stroke. Technology such as ARC shows
promise in bridging the gap [2, 11]. The majority of previ-
ous ARC interventions have been delivered face-to-face
leading to high costs. Incorporating self-management into
an ARC training programme and encouraging self-
monitoring, adherence and self-regulation could provide a
more economical method of delivering this intervention.
In this pilot study, we aim to determine it is possible
to deliver the study protocol over multiple sites in the
home and community. This pilot study will be able to
inform a future multi-centre observer blind parallel
group randomised controlled trial (RCT) of the ARC
treatment.
Research aim
The primary aim of the ACTIVATE study is to deter-
mine the feasibility of a multi-centre (n = 4), observer
blind, parallel group randomised controlled trial of ARC
training to improve gait and physical activity after
stroke.
Study objectives
Primary objectives:
1. To identify monthly recruitment rates to determine
whether it is possible to enrol at least one patient
per month from each study centre.
2. To report participant adherence to ARC
intervention and control treatment arms (provider
observation and exercise diaries).
3. To assess the acceptability and completeness of
proposed methods of data collection to ensure they
are feasible for a definitive trial.
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Secondary objectives:
4. To report participant retention to the study.
5. To report the success of outcome assessor blinding
to participant treatment allocation.
6. To report adverse events in control and
intervention treatments during the study.
7. To report the views of study participants about
undertaking the ARC intervention at home and in
the community.
8. To report the views of providers and clinical
therapists about the study protocol.
9. To gather data to allow reporting of summary
statistics to allow estimation of the sample size
requirements for the definitive trial.
Progression criteria
Progression criteria have been set based upon recruitment,
treatment adherence and data completeness to determine
whether progression to a definitive trial is appropriate.
These criteria and the traffic light system applied are
based upon recommendations from Avery et al. [20].
Potential success criteria:
1. Recruitment of participants: green = an average of
at least four patients per month recruited across the
four sites; amber = an average of at least three
patients per month recruited across the four sites;
red = two or fewer patients recruited per month
across the four sites.
2. Treatment adherence: green = an average of at least
80% (840 out of 1080) supervised and self-
monitored treatment sessions completed across the
intervention and control treatment cohorts
measured by provider observation and exercise
diaries; amber = an average of at least 70% (756 out
of 1080) supervised and self-monitored treatment
sessions completed by participants; red = an average
of 70% or less supervised and self-monitored
treatment sessions completed by participants.
3. Data completeness: green = completion (no missing
data) of over 85% of key outcome measures (7 day
accelerometer measurement; walking speed in the
home; miniBEST and self-completion question-
naires: for full description see the ’Baseline assess-
ment’ section) at 10-week outcome assessment for
all those completing the treatment programmes;
amber = completion of over 70% of key outcome
measures at 10 weeks; red = completion of 70% or
less of key outcome measures at 10 weeks.
Whilst these criteria will be used to evaluate the likely
feasibility of a larger trial, they will primarily be
employed to optimise the study design and identify/
address issues in order to take remedial steps in a timely
fashion. An example of this would be problems around
recruitment.
Methods
Study design
This study is a pilot multi-centre, observer blind, parallel
group randomised controlled trial (RCT), with an alloca-
tion ratio of 1:1.
Study setting
Participants will be recruited from four NHS community
stroke services in the North East of England and from
regional community stroke group meetings. The study
treatments will be delivered in the participant’s homes
and nearby community.
Study population
Eligibility criteria:
Inclusion criteria
 Adults (≥ 18 years) with any stroke subtype.
 Within 24 months of stroke onset.
 Able to mobilise independently > 10 m with/without
stick indoors but presenting with a gait-related
mobility impairment (e.g. gait asymmetry, reduced
walking speed, reduced balance, reduced walking
confidence based on clinical observation or patient
subjective feedback) that would potentially benefit
from this intervention.
 Community dwelling and living within the
community services catchment area of a
participating study centre.
 Able to provide informed consent to participate in
the study.
Exclusion criteria
 Currently undertaking any active physiotherapy.
 Unable to follow study treatment due to significant
cognitive impairment or communication difficulties.
 Diagnosis likely to interfere with adherence to
treatment or predispose to falls, e.g. uncorrected
hearing problems; registered blind; severe visual/
inattention problems as a result of stroke; upper
limb impairment restricting use of cueing device;
able to mobilise 10 metres but extremely slow gait
speed limiting intervention adherence.
 Other neurological or orthopaedic conditions
affecting gait (e.g. Parkinson’s disease, multiple
sclerosis, osteoarthritis, rheumatoid arthritis and
back pain), cardiopulmonary conditions which alter
walking ability (e.g. chronic obstructive disorders,
angina pectoris) and palliative treatment.
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Sample size
We aim to recruit 60 participants in 15 months at a rate
of one patient per trial centre per month. This sample
size has been selected as it is the sample recommended
for pilot studies [21]. We believe that this is a realistic
recruitment rate informed by previous trials [22, 23].
Case ascertainment recruitment and consent
Eligible patients will be identified by healthcare profes-
sionals or by National Institute for Health Research
(NIHR) Clinical Research Network (CRN) Clinical Trial
Officers (CTO) working within NHS stroke services.
CTO’s are part of the hospital stroke team, and there is
regular liaison between themselves and other stroke staff
to identify patients who may be eligible to be invited to
participate in stroke research studies.
Eligible patients will be approached by a healthcare
professional or a CTO, a discussion about the study held
and an information sheet provided. After allowing suffi-
cient time for this information to be considered, and an
opportunity to ask questions, if the eligible patient
wishes to take part, they will be asked if they are happy
for their details to be shared with the study team. The
study team will be alerted and they will contact the pa-
tient to provide more information about the study if ne-
cessary and arrange a visit to obtain consent in writing.
Where a patient is able to provide consent but is unable
to sign the consent form (e.g. because of weakness of the
dominant hand following stroke), consent will be con-
firmed orally in the presence of a witness (an individual
not otherwise involved in the trial) who will sign the
consent form on behalf of the participant.
We will also seek to recruit via advert from commu-
nity stroke groups within the trial catchment area. On
expression of interest, and if eligible, those responding
to the advert will be given a participant information
sheet and an ‘invitation’ card with study contact names
and phone numbers. Their contact details will be taken,
and after being given time to consider participating, the
study team will contact the potential participant to pro-
vide more information about the study and arrange a
visit to obtain consent in writing.
The original consent form will be retained at the study
team base. A copy of the consent form will be filed in
the medical notes at each study site and a further copy
given to the participant. The schedule of events is shown
in Table 1 lists the assessments at each study time point,
with a further detailed study summary in Fig. 1.
Due to the nature of this study and its small size, we
plan for the information sheet and consent form to be
available only in English. However, interpreters and
translation of written material will be considered should
a potentially eligible patient require this.
Loss of capacity to consent to research during
participation in the study
The participants in this research study will be stroke
patients. It is possible that they may temporarily (e.g.
because of intercurrent illness) or permanently (e.g.
because of further stroke) lose the capacity to consent
to this research project. In either case, it is unlikely
that they will be able to continue to participate in a
study which involves self-directed practice. In the
event of likely temporary incapacity, the ‘intervention’
or ‘control’ treatment will be stopped whilst the par-
ticipant is unwell but restarted on recovery if the par-
ticipant wishes to continue. In the event of
permanent incapacity, the participant will be with-
drawn from the study. Data collected prior to with-
drawal will be retained and used in the study analysis
as documented in the patient information sheet.
Study treatments
Development of intervention
To develop the ARC intervention we undertook user
workshops and an acceptability before and after study.
We conducted two user workshops with healthcare pro-
fessionals and stroke survivors exploring the choice of
study metronome, study intervention and control treat-
ment programme content, design of participant hand-
outs/videos and study inclusion/exclusion criteria. Some
issues were highlighted, for example clarity with regard
to the inclusion/exclusion criteria, and changes imple-
mented accordingly prior to commencement of the be-
fore and after study.
Twelve stroke survivors took part in the before and
after study (eight receiving the intervention treatment
and four receiving the control treatment programme).
The study tested the study intervention and control
treatment programmes proposed for the main pilot
RCT and research protocols including outcome as-
sessment. The treatment and research protocols were
feasible and acceptable to stroke participants and pro-
viders. Adherence to the intervention was good, and
no intervention-related adverse events were reported.
The results of the user workshops and the before and
after study have informed the design of the ACTI-
VATE pilot RCT.
Study intervention treatment: auditory rhythmical cueing
and gait and balance exercises
Dose and duration
Participants will be asked to undertake three × 30-min
ARC treatment sessions per week for 6 weeks (total 18
sessions). This dose and duration has been selected based
on findings from previous laboratory-based studies inves-
tigating cueing after stroke [11] and on findings from our
previous successful RCT in Parkinson’s disease [24].
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Materials
An auditory rythmical cueing device will be used. The
auditory rythmical cue will be delivered through the
metronome/phone speaker or through an earpiece at-
tached to the metronome or phone. Depending on the
participants’ choice, they will be provided with either a
standard metronome (Metro Tuner MT-100 by Musedo
with a tempo range of 30–250 bpm) or they will be
shown how to download a free metronome app onto
their phone (‘ZyMi Metronome’ for the Android operat-
ing system or ‘Pro Metronome’ for IOS).
Manuals
Participants will be provided with both paper- and web-
based password-protected video-based training manuals
on how to undertake the ARC treatment. Participants
will also be given an exercise and falls diary.
Procedures
During the 6-week treatment programme, participants
will be taught how to safely undertake a variety of
balance and gait exercises using the ARC device (see
Table 2 for examples of balance and gait exercises).
The ARC treatment will gradually be progressed over
the course of the 6 weeks. In the first session, the
treatment provider will show the participant how to
use the ARC device and at what frequency the ARC
device should be set. The frequency of the auditory
cue will be dependent on the type of exercise and
the needs of the participant. During walking, the
metronome frequency will initially be set at the partici-
pant’s self-selected stepping frequency as this has been
shown to be the most effective method of cueing in stroke
[25]. The auditory cue will have a regular pattern. Each
step will be cued, rather than only the affected or un-
affected lower limb, as this approach has been shown to
lead to stronger auditory motor synchronisation [15]. A
single tone rather than a separate tone to cue both legs
will be used as this approach has been found to be most
preferable in stroke [26].
One session of the ARC treatment per week will be
supervised by the treatment provider, and during this
Table 1 Activate schedule of enrolment, interventions and assessments
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session, ARC exercises will be progressed and new exer-
cises added dependent on the needs of the participant.
During the final 3 weeks of the treatment programme,
supervised sessions will focus on ARC training in com-
munity settings. A menu of verbal cues will be given to
the provider supervising the programme to ensure
consistency of cues. To increase motivation, once partic-
ipants have mastered stepping in time to the beat and
are confident with the exercises, they will have the op-
tion of using music set at the same cueing frequency
during their training sessions. Participants who opt to
exercise to a music beat rather than the metronome will
be provided with a track list of pieces of music with the
correct beat and will be allowed to self-select their own
music.
Mode of delivery
The ARC intervention treatment will be delivered by
two providers (a research physiotherapist and a research
associate). The treatment providers will supervise six of
the ARC treatment sessions over the 6 weeks. The other
12 ARC treatment sessions will be undertaken independ-
ently by participants with telephone support from the
treatment providers as necessary (maximum 6 telephone
calls). All exercises will initially be supervised in order to
determine whether participants are safe to undertake the
Fig 1 Study Summary
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exercises independently. All community walking sessions
with the ARC device will be supervised to ensure safety.
Study control treatment: gait and balance exercises
Dose and duration
Control participants will undertake a matched dose of
balance and gait exercise treatment sessions to the
intervention treatment group, e.g. three × 30-min ses-
sions per week for 6 weeks (total 18 sessions).
Materials
Participants will be provided with paper- and web-based
password-protected video-based training manuals on the
control treatment programme. Participants will also be
Table 2 Examples of exercises included in the ARC training programme
Exercise Repetitions/time Progressions
Balance exercises
1. Weight shift side to side with ARC device 3 × 10 • Without holding on
• Increase the cueing frequency by 5% to work on speed
• Reduce the cueing frequency by 5% to work on control
• Work on movement selectivity
2. Weight shift forward and back with ARC device 10 with the left foot in front
10 with the right foot in front
• Without holding on
• Increase the cueing frequency by 5% to work on speed
• Reduce the cueing frequency by 5% to work on control
3. Stepping forwards and backwards with ARC device 10× forward and back with both feet
leading with the right leg
10× forward and back with both feet
leading with the left leg
• Without holding on
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
4. Side stepping with ARC device Continue side stepping for 2 min • Without holding on
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
5. Turning 180° in both directions with ARC device 5× in one direction
5× in the other direction
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
• Increase the number of repetitions
• Work on the quality of the movement pattern Balance
training Walking
6. Turning 360° with ARC device 3× in one direction
3× in other direction
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
• Increase the number of repetitions
7. Forward stepping onto a step with ARC device 10× forward and back with both feet
leading with the right leg
10× forward and back with both feet
leading with the left leg
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
• Increase the number of repetitions
8. Side stepping onto a step with ARC device 10× stepping both feet onto the step
and onto the other side and returning
to start position
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
• Increase the number of repetitions
Gait exercises
1. Standing march with ARC device 1 min • Increase time
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
2. Walking and turning with ARC device 10 short walks • Increase time
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
• Walking and turning
• Walking backwards
• Walking whilst carrying an object, e.g. cup
3. Manoeuvring between objects with ARC device Repeat each circuit 5 times (e.g.
manoeuvring between two chairs and
returning to start position)
• Increase number of circuits
• Increase the cueing frequency by 5%
• Reduce the cueing frequency by 5% to work on control
• Change the objects to make them more difficult to
manoeuvre around
4. Basic community walking with ARC device 5 min • Increase time/distance walked
• Increase the cueing frequency
• Up and down curbs
5. Advanced community walking with ARC device 5 min • Walking in busy areas, e.g. shopping mall
• Walking on different surfaces, e.g. grass/sand
• Up and down hills
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given an exercise diary to report adherence and a falls
diary.
Procedures
Control participants will undertake the same exercises
and progressions as the ARC intervention treatment
group but without the ARC device and progressions spe-
cific to the ARC treatment programme, e.g. increasing
the cueing frequency. Participants will be given basic in-
structions on the exercises but no cues of an auditory
nature, e.g. any verbal timing cues whilst they undertake
the exercises.
Mode of delivery
The control treatment will be delivered by two providers
(a research physiotherapist and a research associate). In
order to attention match, the control group will be con-
tacted either face to face or by telephone once a week
depending on the needs of the participant to check on
the treatment progression. The other 12 control treat-
ment group sessions will be undertaken independently
with telephone support as necessary (maximum six
phone calls over the 6-week period).
Baseline assessment
A baseline assessment will be performed by a member of
the study team following consent to study participation.
To characterise the cohort and inform treatment de-
velopment, the following data will be collected:
Demographic information: Age, sex, pre-morbid func-
tion (Modified Rankin Scale) [27] pre-morbid walking
status (with/without stick).
Stroke information: Date of stroke; stroke type (Ischae-
mic/haemorrhage); stroke classification subtype (TACS,
PACS, LACS, POCS) [28].
The following measures will be taken at study
baseline:
Stroke-related characteristics: Stroke impairment (Na-
tional Institute of Health Stroke Scale) [29]; disability
(Modified Rankin Scale) [27]; cognition (Montreal Cog-
nitive Assessment) [30]; depression (Physical Health
Questionnaire-9) [31]; fatigue (Fatigue Assessment
Scale) [32]; walking aid use (with/without stick), ankle
foot orthosis (yes/no, type).
Gait, balance and health outcome measures: Ambula-
tory ability (Functional Ambulation Category [33] and
Rivermead Mobility Assessment) [34] spatiotemporal
gait characteristics including gait speed, asymmetry and
variability (4 metre walk test (× 5) recorded both manu-
ally and objectively with an AX3 accelerometer (see full
description of AX3 below); postural control (2-min
standing test objectively measured with an AX3 acceler-
ometer) [35]; balance and gait (Mini Balance Evaluation
Systems Test [36] and Activities-Specific Balance
Confidence Scale) [37]; participation (Stroke Impact
Scale) [38]; health outcome (EQ-5D-3 L) [39].
Seven-day measurement of gait and physical activity
At the baseline assessment, participants will be provided
with an AX3 accelerometer to wear for 7 days before
starting either the control or intervention treatment.
The accelerometer will be collected by the treatment
provider at the first session. Data on spatiotemporal gait
characteristics and broader volume, pattern and variabil-
ity of walking activity will be quantified using methods
previously described [35].
Accelerometer description
The AX3 is a single tri-axial accelerometer-based wear-
able (AX3, Axivity, York, UK, https://axivity.com/, di-
mensions 23.0 mm × 3.25 mm × 7.6 mm). The AX3
weighs 11 g, has a memory of 512Mb and a battery life
of 14 days. AX3 data capture is 100 Hz (16-bit reso-
lution) at a range of ± 8 g. Recorded AX3 accelerations
store locally on the device’s internal memory and then
downloaded upon the completion of each walking trial.
The feasibility, validity and reliability of the AX3 acceler-
ometer has been previously demonstrated for measuring
spatio-temporal aspects of gait and physical activity in a
stroke population in the clinic and the community [35].
Randomisation
Sealed envelope centralised computer-based randomisa-
tion service (https://www.sealedenvelope.com/) will be
used for randomisation. Allocation concealment will be
ensured, as the randomisation code will not be allocated
until after the participant has been consented into the
trial. Randomisation will take place after all baseline out-
come measures have been completed. Once baseline as-
sessments have been completed by the assessors, the
providers of the study treatments will use the sealed en-
velope randomisation service to randomise participants
1:1 into either the ARC intervention or control treat-
ments. Simple randomisations will be used. The ran-
domisation service will be used to number participants.
Outcome assessments—6-week
The following outcomes will be gathered at the end of
the 6-week treatment period.
Gait, balance, physical activity and health outcome
measures
Gait and balance measures collected at baseline will be
repeated (see the “Baseline assessment” section).
Seven-day measurement of gait and physical activity
On completion of the treatments, participants will be
provided with an accelerometer to wear for 7 days.
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Participants will be asked to send the accelerometer back
to the research team after the 7 days in a pre-paid
envelope.
Outcome assessments—10-week
Gait, balance and health outcome measures
Gait, balance and health outcome measures collected at
baseline and 6 weeks will be repeated, in order to assess
retention of post-treatment effects.
Seven-day measurement of gait and physical activity
On completion of this assessment, the participants will
be provided with an accelerometer to wear for 7 days.
Participants will be asked to send the accelerometer back
to the research team after the 7 days in a pre-paid
envelope.
Participant and provider views of the intervention
Participant views of the treatments
A questionnaire with a combination of closed and open
questions will be provided to each of the participants de-
veloped with guidance taken from a previous feasibility
study of physical activity after stroke via self-
management [40].The questionnaires will either be col-
lected by the study providers or returned in pre-paid
envelopes.
Providers’ views of the treatments
The therapist/researcher who has provided both the
treatments will complete a questionnaire with a combin-
ation of closed and open questions specifically designed
for this study in order to ascertain the feasibility of the
treatments.
Qualitative interviews
In order to expand on the findings of the pilot RCT, a
qualitative study will also be undertaken. The views of at
least five ARC intervention participants will be sought,
via interview, alongside the questionnaire data. These in-
terviews will be separate to the main study and under-
taken after the 10-week outcome assessments have been
completed. Opinions on various aspects of the study will
be sought from the first five intervention participants, or
until data saturation has been reached.
Qualitative analysis
Face-to-face semi-structured interviews of approxi-
mately 1 h will be undertaken. From the 30 partici-
pants who will have taken part in the ARC treatment
programme, an estimated sample of five stroke survi-
vors will be interviewed unless data saturation is
reached before this number. Theoretical saturation is
defined as being reached when no new themes
emerge from the data. If data saturation has not been
achieved by this number, further interviews will be
conducted. Purposive sampling will be used to recruit
participants who were in the ARC intervention group
and had completed the study. Purposive sampling has
been chosen to ensure a maximum variation sample
based on gender, age and stroke-related physical
disability.
Potential participants will be invited to take part either
by telephone or by email and given a brief description of
what the interview might address, such as how they felt
about taking part in the study, engagement with the in-
dependent training sessions and any impact they per-
ceive on everyday activities. All participants will be
asked to provide written informed consent, which will
be collected prior to commencing the interview.
Thematic analysis has been chosen to analyse the data
as it is a flexible method that allows themes to emerge
from the data [41] and has previously been used to ana-
lyse data following exercise interventions [42] and phys-
ical rehabilitation following stroke [43]. This ‘rigorous
thematic approach’ can produce an insightful analysis
that answers particular research questions [41]. The-
matic analysis is one of the most commonly used
methods of analysing qualitative data, as it is simple, less
time-consuming and has a flexible approach.
Clinical therapists’ views of the intervention
A workshop will be held with clinical therapists from a
range of local stroke services to provide feedback on the
ARC and control treatments delivered during the RCT.
One therapist from each of the study sites will also be
invited to shadow the delivery of the ARC intervention
during the study to allow for feedback to inform a future
multi-centre trial.
Study withdrawal
No specific study withdrawal criteria have been set. Par-
ticipants may withdraw from the study at any time for
any reason. Should a patient decide to withdraw from
the study, a reason for withdrawal will be sought but pa-
tients can chose to withdraw without providing an ex-
planation. If a participant decides to withdraw, it will
not affect the normal care they receive. Data collected
prior to withdrawal will be used in the study analysis un-
less consent for this is specifically withdrawn.
If a participant does not wish to continue to complete
the treatments, they will be asked if they are willing to
continue to attend outcome assessments.
Clinical teams, local treatment providers or investiga-
tors may also withdraw participants from the study at
any time if they feel it is no longer in the participant’s
interest to continue, for example, because of intercurrent
illness.
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Safety
The safety of the intervention will be evaluated by exam-
ining the occurrence of adverse events and falls.
Falls
Falls diaries will be given to each participant to
complete. The providers (a research physiotherapist and
a research associate) will check these weekly during
face-to-face visits, and any falls between the 6 and 10-
week outcome measures will be confirmed by the out-
come assessor. Throughout the trial, the following defin-
ition of a fall will be applied: ‘A fall is described as an
event in which the participant has lost their balance and
landed on the floor or ground or lower level, including a
slip or trip’ [44]. The falls diaries will be collected by the
study team on the final outcome assessment visit.
Safety evaluation
The standard definitions for adverse events will be used
in this study:
Adverse event
Any untoward medical occurrence in a subject to whom
a study intervention or procedure has been adminis-
tered, including occurrences which are not necessarily
caused by or related to that intervention. An adverse
event (AE), therefore, does not necessarily have a causal
relationship with the treatment. In this context, ‘treat-
ment’ includes all interventions (including comparative
agents) administered during the course of the study.
Medical conditions/diseases present before starting
study treatment are only considered adverse events if
they worsen after starting study treatment.
Related AE
Related AE is an AE that results from administration of
any of the research study procedures. All AEs judged by
either the reporting investigator or the sponsor as having
reasonable causal relationship to a study procedure qual-
ify as ‘related adverse events’. The expression “reason-
able causal relationship” means to convey in general that
there is evidence or argument to suggest a causal
relationship.
Causality
The assignment of the causality should be made by the
investigator responsible for the care of the participant.
All adverse events judged as having a reasonable sus-
pected causal relationship to a study procedure are con-
sidered to be related adverse events. If any doubt about
the causality exists, the local investigator (PI) should in-
form the chief investigator. In the case of discrepant
views on causality between the investigator and others,
all parties will discuss the case. In the event that no
agreement is made, the main REC and other bodies will
be informed of both points of view.
Serious adverse event
Serious adverse event (SAE) is an untoward occurrence
that:
 Results in death
 Is life-threatening (refers to an event in which the
subject was at risk of death at the time of the event;
it does not refer to an event which hypothetically
might have caused death if it were more severe)
 Requires hospitalisation, or prolongation of existing
hospitalisation
 Results in persistent or significant disability or
incapacity
 Consists of a congenital anomaly or birth defect
 Is otherwise considered medically significant by the
investigator
Medical judgement should be exercised in deciding
whether an AE is serious in other situations. Important
medical events that are not immediately life-threatening
or do not result in death or hospitalisation but may
jeopardise the patient or may require intervention to
prevent one of the other outcomes listed in the defin-
ition above, should also be considered serious.
Unexpected adverse event
Unexpected adverse event is an adverse event that is not
an expected occurrence in the circumstances of this
trial.
Recording and reporting of adverse events
This study will only report adverse events which are
considered to be serious.
Serious adverse events exclude:
 Pre-planned hospitalisations
 Scheduled treatment for pre-existing conditions.
The capture of potential SAEs will take place at the
study outcome assessments by including the following
questions in the outcome proforma: “are there any new
medical problems since the last study assessment?” In
addition, we will specifically enquire about falls in re-
sponse to the participants falls diaries. For any events
which fulfil the criteria to be a SAE and are unreported,
the study SAE form will be completed.
Events considered to be SAEs will subsequently be
documented onto a separate study SAE form, and a
causality and expectedness assessment will be per-
formed. As study investigators or other members of the
research team may become aware of SAEs at times other
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than at outcome assessment appointments, the SAE
form will also be used to directly capture these events.
Initial/provisional SAE reports can be made by tele-
phone or email to the study co-ordinating centre. All
initial/provisional reports must be followed by a fully
completed SAE form. If incomplete information is avail-
able at the time of this initial report, further information
must be provided on a follow-up form as soon as it is
available. All SAEs regardless of causality or expected-
ness will be reported to the chief investigator and trial
sponsor (Northumbria NHS Foundation Trust) in line
with local policies. The main REC will be notified of re-
lated and unexpected SAEs within 15 days of the chief
investigator becoming aware of the event.
Fidelity
The providers of the intervention and control treatments
will be trained in the delivery via a face-to-face training
session and through provision of a handbook to stand-
ardise treatment delivery. Alongside the handbook, pro-
viders will have a catalogue of videos of the delivery of
the treatments to aid delivery skills.
Providers will be observed by an external member of
the study team to ensure adherence to treatment deliv-
ery, accommodate for provider differences and prevent
provider drift. These observations will be made once
every month during the first 3 months of the trial. They
will then be observed once every 3 months for the rest
of the trial. Providers will keep written records of treat-
ment delivery to ensure delivery of the correct dose of
treatment.
In order to ensure participant receipt and correct en-
actment of the treatments, participants will be shown
each exercise, and then asked to describe and demon-
strate the exercise back to the provider. Participants will
also be asked to confirm how many ARC exercises they
have been asked to undertake and will be provided with
an exercise diary to document enactment of the exer-
cises. The ARC exercise diary will be collected by the
study team on the final outcome assessment visit. The
outcome assessor will also be observed whilst conduct-
ing outcomes measures on three occasions across the
duration of the study.
Study data collection
All study data will be entered locally by the study team
onto a secure online database (MACRO) maintained by
Newcastle Clinical Trials Unit. Pseudo-anonymised partici-
pant identification codes will be used. Study paper CRF’s
will be kept securely in the local investigator site file.
Blinding
This study will be single blinded. Outcome assessments
will be performed by researchers blinded to treatment
allocation. After each assessment, the researcher will be
asked to record whether they have unintentionally be-
come aware of treatment allocation. Success of outcome
assessment blinding will be reported. Emergency un-
blinding will not be required for this study.
Data analysis
Objectives 1–3: Recruitment will be described as rate/
month (total and per site). Adherence will be described
using data from the exercise diaries (number of planned
sessions completed). Acceptability and completeness of
methods of data collection will be described using per-
centages from both treatments.
Objective 4: Retention will be described as percentage
from both treatments.
Objective 5: The success of outcome measurement
blinding will be described (%).
Objective 6: Adverse events pertaining to the study for
each treatment will be described (number of events).
Objective 7: The views of study participants about
undertaking the ARC treatment at home and in the
community will be described. Summary statistics will be
used for answers to closed questions and open questions
will be thematically analysed.
Objective 8: The views of providers and clinical thera-
pists about delivery of the study treatments will be de-
scribed. Summary statistics will be used for answers to
closed questions and open questions will be thematically
analysed.
Objective 9: As this is a pilot study, statistical compari-
sons of clinical outcomes (e.g. dynamic gait index, see
above) and accelerometer data between treatments will
not be undertaken and data will be presented as sum-
mary descriptive statistics. To determine which outcome
measures to take forwards to a main trial, we plan to re-
view data completeness, patient/staff feedback about ac-
ceptability and any new emerging literature about most
appropriate measures, to inform decisions. This review
will also determine the most appropriate primary out-
come measure. Data collected for this selected primary
outcome measure (e.g. standard deviation) will subse-
quently be used as appropriate by statisticians to inform
a power calculation for a definitive trial.
Policies, procedures and dissemination
Lone worker policy
The study team and intervention providers will follow
the relevant Trust and/or Newcastle University lone
workers policy when collecting study data and providing
therapy in people’s homes.
Confidentiality
Personal data will be regarded as strictly confidential.
The study will comply with the Data Protection Act,
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2018, General Data Protection Regulations and Caldicott
Principles. All study records will be kept at research cen-
tres and/or Newcastle University with restricted access.
All trial documentation will be retained for future audit
in line with the sponsor policies. Participants will not be
identified in any report or publication arising from this
research. Any feedback comments or quotes will be
anonymised.
Indemnity
NHS Trusts participating in the study have liability for
clinical negligence that harms individuals toward whom
they have a duty of care. NHS indemnity covers NHS
staff and academic staff with honorary contracts con-
ducting the trial for potential liability in respect of negli-
gent harm arising from the conduct of the study. The
Northumbria Healthcare NHS Foundation Trust is a
sponsor, and through the sponsor, NHS indemnity is
provided in respect of potential liability and negligent
harm arising from study management. Indemnity in re-
spect of potential liability arising from negligent harm
related to study design is provided by NHS schemes for
those protocol authors who have their substantive con-
tracts of employment with the NHS and by Newcastle
University Insurance schemes for those protocol authors
who have their substantive contract of employment with
the university. This is a non-commercial study, and there
are no arrangements for non-negligent compensation.
Data management
A web-based data entry tool will be developed and ad-
ministered by Newcastle Clinical Trials Unit for the
study. A database manager will monitor data quality
under supervision of the project team.
Data monitoring
A formal data monitoring committee or equivalent body
will not be convened, as the study is of minimal risk and
considered too small and of short duration to have
official monitoring structures. However, there will be
continuous ad hoc monitoring undertaken by study
management. Safety data will be reviewed at project
meetings. The treatment providers will closely monitor
the well-being of individual participants. Stopping the
study will be considered if the study management ad-
vises against continuing, for example study-related ser-
ious adverse events or falls. The chief investigator has
the ultimate authority to stop or modify the study.
Data sharing
We will share anonymised data (referenced only with
study number) with approved collaborators both nation-
ally and internationally (inside and outside of the EU)
for scientifically sound, peer reviewed studies. Data
sharing offers a more open approach that allows us to
maximise the impact of the study for the health and
wellbeing of the population.
Data sharing will be managed by our data manage-
ment committee according to the following procedures:
1. Collaborators interested in accessing data from the
study will send the data management committee an
expression of interest, for example, using data
request from or via research platforms data portals.
2. The committee will then review the data request. If
required, the data management committee may
request changes to the proposed study by
collaborators. The data management committee
may then approve or reject the proposed study.
3. A data use agreement will be drafted and signed by
both parties.
4. As agreed by data managing committee and
collaborators, and according to signed data
agreement forms, anonymised data will be
transferred to the collaborators.
Data will be securely transferred to collaborators. Data
will be securely stored by collaborators for a fixed dur-
ation, as stated in the signed data use agreement. Only
anonymous and unidentifiable data will be sent.
Auditing
Progress and quality of trial delivery via fidelity checks
will be monitored prospectively by the project manage-
ment group at scheduled meetings. As this is a feasibility
study, it will not be audited by an independent auditing
company.
Dissemination of results
The data will be the property of the chief investigator
and co-investigator(s). Publication will be the responsi-
bility of the chief investigator. The study will be pre-
sented at national and international conferences and
reported in peer-reviewed journals. Reports will be writ-
ten for the study sponsor and regulatory bodies. A sum-
mary of the results will be sent to study participants.
Anonymised data will be provided to research databases
as requested (e.g. the Cochrane Collaboration, the
Virtual International Stroke Trials Archive (VISTA) to
enable future meta-analyses). Yearly reports will be sent
to the funder.
Discussion
The main aim of this RCT is to determine whether de-
livery of a home/community-based programme of exer-
cises using auditory rhythmical cueing to improve gait
and physical activity in stroke survivors is acceptable
and feasible. A significant amount of the stroke survivor
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population reports gait and balance problems severe
enough to interfere with their daily functioning and abil-
ity to move freely in the community.
The proposed exercise programme is based on gait
and balance exercises delivered in the home, with a
combination of supervised and self-managed sessions.
Although previous studies have assessed ARC interven-
tions, these have been limited in their design by their
focus on laboratory settings/treadmill walking or by only
assessing patients ‘stepping-in-place’. By expanding and
adapting the ACTIVATE before and after study, this
study will provide valuable feasibility data on recruit-
ment, delivery of intervention and measuring outcomes
over multiple sites and assess whether it is possible to
deliver the ARC intervention in the real world, both in
the home and the wider community. This will support
moving forward with a multi-centre efficacy trial of
ACTIVATE.
Trial status
Patient recruitment and intervention began in November
2018. The ACTIVATE trial has recruited 16 participants
out of our target of 60 at the time of submission of this
manuscript (April 2019).
Protocol number and date: Version 2 dated 11.12.2018
Protocol Amendment number 1 Authors SAM, PM.
Revision chronology: 11.12.2017 original. 11.12.2018
Amendment number 1
Primary reason for amendment: changes in sections
A27-1, A28 and A29 regarding increasing recruitment
potential and additional recruitment materials.
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